RANI - Rani Therapeutics Holdings, Inc. Total Debt to Capital

Rani Therapeutics (RANI) is a pioneer in the field of oral delivery of biologics via the RaniPill system. The price indicator on the chart reflects a debt load of 0.09. The robo-pill technology replaces injections by delivering the drug directly into the intestinal epithelium. The business relies on automated facilities equipped with precision machinery, where the assembly of specialized capsules is conducted in sterile zones with stable capacity utilization.

Rani Therapeutics (RANI) is investing in the development of robotic capsules, where high engineering costs prior to FDA approval temporarily offset operational efficiency. The total liabilities-to-equity ratio quantifies this risk by measuring the proportion of debt financing within the balance sheet structure to assess solvency, which clearly reflects the trend of financial dependence via the debt-to-equity ratio.